Inclusion criteria: Randomized clinical trials (RCTs) and retrospective observational studies evaluating patients with T2DM or impaired glucose tolerance (IGT) with/without complications receiving canakinumab, compared with placebo or standard therapy and reporting about glycemic indicators including HbA1C or blood sugar levels (BSL) or insulin levels and/or inflammatory indicators including hsCRP or interleukin-6 (IL-6) were included. The gene discussed is INS; the disease is Impaired glucose tolerance.